deltatrials

Hepatitis c virus infection Trials in Orlando, United States

Conditions / Hepatitis c virus infection / Orlando, United States

Clinical trials for Hepatitis c virus infection investigate a range of treatment strategies and patient populations.

15 total trials for this combination

Showing top 10 of 15 trials

Trials

NCT ID Title Status Phase
NCT02378961 Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Non-Genotype 1 HCV Infection COMPLETED PHASE2
NCT02639247 Safety and Efficacy of SOF/VEL/VOX FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor COMPLETED PHASE3
NCT02201940 Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic HCV Infection COMPLETED PHASE3
NCT03022981 Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir in Adolescents and Children With Chronic HCV Infection COMPLETED PHASE2
NCT02201953 Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 24 Weeks in Adults With Chronic Genotype 3 HCV Infection COMPLETED PHASE3
NCT02114177 Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Chronic Hepatitis C Virus Infection Without Cirrhosis COMPLETED PHASE3
NCT02510300 A Registry for Adolescent and Pediatric Participants Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials TERMINATED
NCT02220998 Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 12 Weeks in Adults With Chronic Genotype 2 HCV Infection COMPLETED PHASE3
NCT02378935 Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Genotype 1 HCV Infection COMPLETED PHASE2
NCT02292706 A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection TERMINATED

Related Pages